GIGABYTE
3.1.2022 07:05:09 CET | Business Wire | Press release
GIGABYTE is joining CES Virtual with its website extension – INDUSTRY – to present products and solutions that propel digital transformation in industries such as 5G & telecom, automotive, creative & gaming, data centers , manufacturing, and retail.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005431/en/
GIGABYTE takes pride in having an incredibly deep portfolio of enterprise products that support cloud, edge, and data centers. There are over 75 servers for AMD EPYC CPU alone, as well as Intel Xeon Scalable CPU, and over 10 servers for Ampere Altra CPU, and not to forget over 20 server motherboards. GIGABYTE offers edge servers developed based on Arm architecture. These high-density Arm servers , using Ampere’s massive 80 / 128 core CPU, provide the performance, storage, network, and above all, the flexibility to be deployed for the next generation of telecommunications where processing work needs to be done on-site. GIGABYTE’s server solutions are also applicable to various industries, and are highly valued by large and small high-tech companies, medical, scientific, academic research, and public institutions, etc., and have successfully assisted them in innovation and breakthroughs in their fields.
Our industries are undergoing an invigorating metamorphosis as AI, HPC, IoT, and other breakthroughs bring about a paradigm shift. MyelinTek Inc., an investee company of GIGABYTE developed a deep learning system MLSteam, which includes optimized AI software stacking and comprehensive management tools in a user-friendly interface to make it easier for scientists to train and develop AI integration for autonomous vehicles. With the rapid development of Advanced Driver Assistance Systems (ADAS ) technology, GIGABYTE designs decision-making control units for different types of autonomous vehicles, as well as customized products such as ADAS ECUs, TCUs, assisting vehicles designers to develop their ideal products and improve the automotive industry.
GIGABYTE has years of proven experience in embedded computers and brought its latest generation of embedded systems to increase the operability of storage, logistic, and manufacturing facilities while lowering labor and management costs with the innovation of AGV, AMR, and Industrial Automation Security System. In the post-pandemic era, GIGABYTE’s embedded solutions integrated with AI and IoT technology helped automate the operation and management of open space rentals, allowing such new services to flourish.
GIGABYTE’s reputation to invent top-notch products with innovative VRM and thermal design makes the task to optimize overclocking performance on the latest Intel® Core™ CPUs easy and effective. The Z690 series motherboards provide beyond the essential features and power for both professional creators and gamers alike. Performance is the key to both immersive gameplay and smooth workflow, and GIGABYTE has taken performance above all else with this generation’s AORUS gaming laptops and the AERO creator laptops which are to be released in early 2022.
GIGABYTE has recently launched INDUSTRY to demonstrate its most pivotal products and solutions for different industries. One of the biggest highlights of the platform is its live chat function. GIGABYTE has arranged experts, who have keen insights on the industries, to standby the live chat and answer questions and inquiries made by CES visitors and buyers as they would at the physical venue. The live chat uses AI-generated avatars to show the status of its live experts, and also as a way to embrace the ‘metaverse ’ where virtual merges with reality. The INDUSTRY platform will host all products and solutions GIGABYTE is presenting at CES including trendy topics highlighted in the event and more. GIGABYTE welcomes all visitors to connect through this digital platform and see their industries from different perspectives.
INDUSTRY: https://industry.gigabyte.com
Visit GIGABYTE on CES Digital: https://gbte.tech/ces2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005431/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom